Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

JW (Cayman) Therapeutics Co. Ltd. (JNY) Stock Price & Analysis

JNY Stock Chart & Stats

€0.24€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.2€0.225€0.259 Mar14 Apr21 May28 May
Day’s Range
EUR 0.23 - EUR 0.24
52-Week Range
EUR 0.16 - EUR 0.43
Previous Close
EUR 0.24
Volume
0
Average Volume (3M)
0
Market Cap
EUR 105.67M
Enterprise Value
EUR 507.99M
Total Cash (Recent Filing)
EUR 392.02M
Total Debt (Recent Filing)
EUR 254.85M
Price to Earnings (P/E)
―
Beta
0.84
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Gross-margin Improvement

Strong 2025 revenue growth, together with a higher gross margin, indicates improving commercial traction and better economics on sales. If sustained, this combination can expand operating leverage, support investment in CAR-T development, and move the business closer to profitability.

Improved Operating Cash Control

The substantial reduction in operating cash burn signals better cost control and/or working-capital dynamics. Although cash generation remains negative, this direction of change can extend funding runway and reduce the pace at which external capital is needed while the company scales its therapies.

Manageable Leverage

Moderate leverage means debt is not currently the primary balance-sheet constraint, giving JW Therapeutics more flexibility than a highly indebted biotechnology peer. This supports continued investment in development and commercialization without excessive debt-service pressure.

Bears Say

Deep Ongoing Unprofitability

The company remains far from break-even despite narrowing losses, so revenue growth has not yet translated into sustainable earnings. Persistent operating losses can constrain reinvestment, weaken financial resilience, and increase dependence on successful commercialization or additional funding.

Persistently Negative Free Cash Flow

Continued negative free cash flow means the business is not yet self-funding its operations and development programs. Unless cash generation improves materially, JW Therapeutics may need external capital, creating funding dependence and limiting flexibility in allocating resources.

Equity-base Erosion

Accumulated losses have reduced the company’s capital base, weakening balance-sheet resilience even though leverage remains manageable. Further equity erosion could diminish financial flexibility and make future investment, financing, or expansion decisions more dependent on improving operating results.

JW (Cayman) Therapeutics Co. Ltd. News

JNY FAQ

What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was €0.16 and its highest was €0.43 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is €105.67M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 27, 2026. The company reported -€0.016 earnings per share for the quarter.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,883,360 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -€0.016 in its last earnings report. Following the earnings report the stock price went up 4.464%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in DE:JNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology